DEFA14A ·Filed Apr 23, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-173686
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's next 10-Q filing for any updates on financial performance or guidance, as this proxy statement contains no new financial information.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PCVX ▼ -2.44% at T+60d
NEUTRAL call ✗ call lost -2.44% · α vs SPY -7.52% · entry $59.49 → $58.04
Entry anchored
Apr 23, 03:59 PM ET
via exchange tick
T+1d
+0.39%
call +0.39% · α +0.22%
$59.72
settled 5mo ago
T+5d
-3.78%
call -3.78% · α -4.69%
$57.24
settled 5mo ago
T+20d
-20.34%
call -20.34% · α -24.37%
$47.39
settled 4mo ago
T+60d
-2.44%
call -2.44% · α -7.52%
$58.04
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • The meeting will be held on June 15, 2026.
  • Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
  • The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.
  • The compensation of the named executive officers will be approved on an advisory basis.
  • The Board recommends voting 'For' on all proposals.
  • The filing is routine and does not contain any material financial data or significant corporate actions.

Financial Impact

No material financial impact. The filing is a routine administrative document.

Risk Factors

  • The lack of new financial information or strategic updates in the filing means investors must wait for the next quarterly report for material updates.
  • The advisory vote on executive compensation could be a point of contention for shareholders, although it is non-binding.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-173686
Document: 0001193125-26-173686-index-headers.html0001193125-26-173686
Document: 0001193125-26-173686-index.html0001193125-26-173686
Document: 0001193125-26-173686.txt0001193125-26-173686
13 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.92 $61.58▲ +10.12%▲ +10.72%$56.69 (+1.38%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jun 26, 2026
13w ago
144
NEUTRAL ★ 3/10
$57.72 $54.66▼ −5.30%▼ −5.02%$56.69 (−1.78%)
Jun 23, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$53.87 $56.00▲ +3.95%▲ +2.02%$56.69 (+5.23%)
Jun 19, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.11 $56.20▲ +7.85%▲ +8.00%$56.69 (+8.79%)
Jun 2, 2026
17w ago
Press Release
NEUTRAL ★ 4/10
$46.93 $58.39▲ +24.42%▲ +25.42%$56.69 (+20.80%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$51.48 $46.93▲ +8.84%▲ +11.97%$56.69 (−10.12%)
Apr 23, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $47.39▼ −20.34%▼ −24.37%$56.69 (−4.71%)
Apr 1, 2026
26w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $57.32▼ −2.02%▼ −11.74%$56.69 (−3.09%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access